Women are twice as likely to suffer from Alzheimer's as men. Scientists have figured out why
Now scientists say they may be on their way to understanding why that's the case - pinpointing two stark differences between men and women. Firstly, women have different chromosomes than men. They also undergo menopause: a process that occurs when a woman's reproductive hormones naturally decline starting in her 40s and 50s.
One in three older Americans dies with Alzheimer's, or another dementia, according to the Alzheimer's Association. Almost two-thirds of Americans with Alzheimer's disease are women.
'Epidemiologically, we see that for almost all neurological diseases, there are differences in how many biological women and men are affected,' Anna Bonkhoff, resident and research fellow in neurology at Harvard Medical School and Mass General Brigham, explained in a recent interview. 'There's a tendency, for example, in [multiple sclerosis] and migraine for more females to be affected, while it's the contrary for brain tumors and Parkinson's.'
'Just based on these numbers, you get the feeling that something needs to underlie these differences in terms of the biology,' she added.
Looking inside the body, while women have two 'X' chromosomes, men have an 'X' and a 'Y.' Chromosomes are thread-like structures of DNA inside our cells that carry hundreds or even thousands of genes. Genes determine a person's physical characteristics. Differences between genes held on the X and Y chromosomes may give women an increased chance of developing Alzheimer's disease.
Recent research has shown that genes on the X chromosome are related to Alzheimer's disease, including that women with Alzheimer's live longer than men with the disease due to their second X chromosome.
'A lot of genes for the immune system and regulating brain structure are located on the X chromosome, so the dosages differ to certain degrees between men and women. That seems to have an effect,' said Bonkhoff.
Women's different dominant hormones — such as estrogen, which acts on the brain — could also play a role.
'Menopause is part of the puzzle, probably one of the bigger ones,' Bonkhoff said. 'I'm not saying it's the only one — aging is relevant by itself, and there's a lot of interesting research looking at what aging does to the immune system that seems to have implications for cognitive changes.'
During menopause, when ovaries stop producing estrogen and progesterone, some women turn to hormone replacement therapy. The practice offers relief for symptoms of lower hormone levels in menopause such as hot flashes. But for some women it may increase their risk of dangerous medical conditions, including heart attacks, strokes, breast cancer, blood clots and gall bladder disease, according to the Centers for Disease Control and Prevention.
Women who received hormone replacement after age 70 also have significantly higher levels of the protein known as 'tau,' according to Rachel Buckley, associate professor of neurology at Harvard Medical School. The accumulation of tau is a hallmark of Alzheimer's disease. They also suffered higher cognitive decline.
Buckley published those findings last March in the journal Science Advances. But further research is needed to understand these associations.
'We work with a lot of secondary data that already exists, and that's great but there are limitations to what we can do with it,' Buckley said. 'We're trying to see if we can set up a new study design where we can really look at the time of menopause, what is changing in the blood, what is changing in the brain, what is changing in cognition, and how that might be associated with later life risk.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
11 minutes ago
- The Independent
Brooke Hogan has questions about her dad's death
WWE legend Hulk Hogan passed away on 24 July at the age of 71, with his funeral held privately in Florida. Medical records obtained by The Independent indicate his cause of death was a heart attack, alongside a previously unknown diagnosis of chronic lymphocytic leukaemia. Hogan's estranged daughter, Brooke Hogan Oleksy, has publicly questioned the circumstances surrounding his death. Brooke shared a news article on Instagram highlighting concerns about a 'quick cremation without autopsy' and further discussed these doubts on a radio show. She specifically raised questions about the undiagnosed leukaemia and the absence of an autopsy, despite medical records confirming acute myocardial infarction and chronic lymphocytic leukaemia.
The Independent
11 minutes ago
- The Independent
Trump calls RFK Jr ‘three or four times a week' with the same question
Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up 'three or four times a week' to hound him with the same question. Kennedy was speaking at an event Monday with Secretary of Agriculture Brooke Rollins to push a policy banning sugary drinks, candy and junk food from the Supplemental Nutrition Assistance Program, as part of his 'Make America Healthy Again' agenda. Six months into his second term, Trump wants to know 'why aren't people healthier yet,' Kennedy told reporters at the press conference. 'We have full support from the president,' Kennedy said. 'He wants this done. He promised to make America healthy again, and he's gonna do that.' 'He called me last night,' Kennedy added, referring to the president. 'He calls me three or four times a week and says, 'Where are you? Why aren't people healthier yet?' So he's keeping me under pressure.' Monday's event was promoting a policy adopted by West Virginia, Texas, Colorado, Louisiana, Oklahoma and Florida, barring SNAP participants from using food stamps to buy junk food. They join Arkansas, Idaho, Utah, Iowa, Indiana and Nebraska in the SNAP waiver initiative. SNAP is a lifeline that keeps more than 41 million Americans, or 12 percent of the population, from going hungry. More than 13 million recipients are children. Over the past 20 years, lawmakers in several states have proposed stopping SNAP from paying for everything from bottled water and soda to chips, ice cream and 'luxury meats' such as steak. Critics said that the SNAP waiver 'ignores decades of evidence showing that incentive-based approaches — not punitive restrictions — are the most effective, dignified path to improving nutrition and reducing hunger,' said Gina Plata-Nino, a deputy director at the Food Research & Action Center, a nonprofit advocacy group. Trump passed the largest-ever cuts to the program in his signature 'One Big, Beautiful Bill' by restricting eligibility for SNAP enrollment and diverting a significant chunk of the program's costs to states.
The Independent
11 minutes ago
- The Independent
‘We will work collaboratively': Big Pharma admits it is discussing Trump's plan to lower drug prices
Pfizer CEO Albert Bourla says that his company and other large pharmaceutical firms are looking at working with the Trump administration to make more of their medicines available at lower costs to consumers. In a conference call with investors on Tuesday to discuss second-quarter earnings, Bourla said, 'We have serious discussions in the industry,' according to BioPharma Dive. 'I'm connected very often individually with all the major companies, and they are all ready to roll up their sleeves and execute something like that,' he added. Bourla leads Pfizer and is the board chair of PhRMA, the industry lobbying group. Pfizer and its partner Bristol Myers Squibb recently revealed plans to make their blood thinner Eliquis available at a lower price online. The firm previously started a direct-to-consumer service that lets patients book telehealth appointments, schedule vaccinations, and fill some prescriptions. 'We think it is a fantastic way to go ahead, so we will work collaboratively to do it,' said Bourla. Eli Lilly and Novo Nordisk, both makers of obesity drugs, have also put forward more ways that patients who pay in cash can access the weight-loss drugs directly. Other companies are also showing interest in the effort, looking at ways to make drugs available without pharmacy benefit managers — the middlemen getting rebates from drugmakers that insurers claim lower the overall cost, but not in ways that are clear to a patient filling a prescription. In letters to 17 drugmakers last week, Trump demanded that direct-to-consumer options be expanded. He said he would use 'every tool' available to him if the companies don't act to lower the cost of their products to prices seen in other industrialized countries. Trump has indicated that the policy would be limited to Medicaid, and analysts aren't unified on how much of an impact it would have. During the call on Tuesday, Bourla noted that he's in 'active discussions' with the 'highest levels of the U.S. government,' according to BioPharma Dive. That includes speaking to Trump, Health and Human Services Secretary Robert F. Kennedy Jr., and the Administrator of the Centers for Medicare and Medicaid Services, Mehmet Oz. 'The letter asks a lot from us,' said Bourla. 'But we are engaged in productive discussion with them and in general, I'm happy with the way that they listen to us.' Amid an investigation into pharmaceutical imports, the Commerce Department is expected to impose sector-specific tariffs. Trump told CNBC on Tuesday that his administration would at first put in place smaller tariffs on pharmaceuticals, which could subsequently rise to as much as 250 percent. While the tariffs would be expensive for drugmakers, analysts think that a phase-in period would mean that many companies could change their supply chains to avoid the worst of the financial repercussions, BioPharma Dive noted. Most of the biggest drugmakers have already revealed significant investment in manufacturing in the U.S. Pfizer indicated that it would be able to take on the tariffs this year, including any possible changes to its pricing, and still meet its financial forecast of revenues measuring between $61 billion and $64 billion. Trump has made impossible promises on drug prices, saying he's cut them by up to 1,500 percent. 'You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500 percent. I don't mean 50 percent, I mean 14 — 1,500 percent,' Trump told reporters on Sunday. This is inaccurate, as cutting prices by more than 100 percent would mean that consumers are being paid to take the drugs. The director of health policy at the University of Southern California's Schaeffer Center, Geoffrey Joyce, called the claim 'total fiction.' Mariana Socal is an associate professor of health policy and management at Johns Hopkins University. 'I find it really difficult to translate those numbers into some actual estimates that patients would see at the pharmacy counter,' she said. 'It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people,' a White House spokesperson said.
